Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $463.00 -0.15 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down

Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.

Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%

Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.

Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View

Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.

Celgene (CELG) Q3 Earnings Beat, Otezla, Revlimid Sales Rise

Celgene (CELG) beats on earnings and revenues in the third quarter of 2019 on strong performance from Otezla and Revlimid.

Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates

Vertex (VRTX) encourages investors with better-than-expected earnings in Q3. However, the top line misses the mark.

Will Vertex Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Vertex Pharmaceuticals.

Vertex Pharmaceuticals (VRTX) Beats Q3 Earnings Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 7.89% and -0.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology

Zacks.com featured highlights include: Columbia Sportswear, Boot Barn, Vertex Pharmaceuticals, Upland Software and Spotify Technology

Sanghamitra Saha headshot

Looking for an Earnings Beat? 5 Top Picks

5 top-ranked stocks likely to beat on earnings are great investment picks for stellar gains.

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, PulteGroup, Skyworks Solutions, Lennar and Kansas City Southern

Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings?

During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.

Nalak Das headshot

5 Top Volatility-Defying S&P 500 Stocks of Past Month

Year to date, the benchmark S&P 500 Index has rallied 20.1%, an impressive performance after a disappointing 2018, when it lost 6.6%.

Top Ranked Momentum Stocks to Buy for October 25th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 25th:

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.

Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance

Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.

AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View

AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.

Factors Setting the Tone for Celgene (CELG) Q3 Earnings

Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q3 results.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

Key highlights of the past week include acquisition news, and regulatory and pipeline updates.

The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.

The Zacks Analyst Blog Highlights: Chipotle Mexican Grill, Vertex Pharmaceuticals, American Electric Power Company, Verizon Communications and V.F.

What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?

Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.

Is Walgreens Boots (WBA) Likely to Disappoint in Q4 Earnings?

Persistent de-emphasizing of tobacco is hurting growth, which should get reflected in the upcoming quarterly results of Walgreens Boots Alliance (WBA).